Equities research analysts at B. Riley issued their FY2029 earnings per share estimates for Trevi Therapeutics in a research ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Healthcare Services (HCSG – Research Report) and ...

Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Oct. 30, 2024 /PRNewswire/ -- Trevi Therapeutics (NASDAQ:TRVI), Inc. (Nasdaq: TRVI), a ...

Trevi Therapeutics (NASDAQ: NASDAQ:TRVI), a biopharmaceutical company dedicated to developing treatments for chronic coughs and idiopathic pulmonary fibrosis (IPF), provided an... ByInvesting.com • 12 ...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in ...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients ...

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...